Prevalensi dan Faktor Risiko Kejadian Efek Samping Obat pada Pasien TB-MDR: Literature Review
Prevalence and Risk Factors for Adverse Drug Reactions in MDR-TB Patients: Literature Review
Abstract
Latar belakang: Efek samping obat merupakan masalah kesehatan penting yang sering terjadi pada pengobatan Tuberculosis Multi Drug Resistant (TB-MDR) dan berpengaruh pada kepatuhan pengobatan dan keberhasilan pengobatan.
Tujuan: Untuk mengetahui gambaran efek samping dan faktor risiko yang berhubungan dengan terjadinya efek samping obat pada pasien TB-MDR.
Metode: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). Penelusuran literatur pada database Pubmed, Proquest, Scopus dan Science Direct. Kata kunci: “adverse event” “adverse drug reaction” “drug resistant” “MDR” “tuberculosis” “predicted factor”. Kriteria inklusi literatur berbahasa Inggris, full text, free open access, rentang waktu publikasi 10 tahun terakhir, dan memiliki desain studi analitik.
Hasil: Berdasarkan hasil penelusuran di 4 database diperoleh total 468 artikel yang kemudian dilakukan proses skrining dan kelayakan melalui kriteria inklusi dan eksklusi hingga didapatkan 6 artikel yang dilakukan sintesis.
Kesimpulan: Prevalensi efek samping pasien TB-MDR adalah 40-80,7%. Mayoritas pasien mengalami efek samping ototoxicity, arthralgia, gastrointestinal disease, psychiatric disturbance, hepatotoxicity, dermatologic disease. Faktor risiko yang berhubungan dengan efek samping adalah usia lebih tua, berat badan tinggi, status pasien yang bekerja, riwayat efek samping, riwayat pengobatan TB sensitive obat (SO), komorbiditas, alkohol, dan perokok aktif, paduan pengobatan TB-MDR (paduan jangka panjang, paduan individual, paduan tanpa bedaquiline), tidak menerima transportasi kontrol bulanan, menerima DOT (directly observed therapy) dari fasilitas kesehatan perifer, dan keterlambatan pelaporan kasus TB MDR. Sedangkan faktor yang menurunkan risiko efek samping adalah paduan pengobatan dengan bedaquiline, underweight dan menerima pasokan makanan
References
Alomar MJ. Factors Affecting the Development of Adverse Drug Reactions (Review Article). Saudi Pharmaceutical Journal. April 2014;22(2):83–94.
World Health Organization. Global Tuberculosis Report 2022. Geneva: World Health Organization; 2022.
Gupta A, Kumar V, Natarajan S, Singla R. Adverse Drug Reactions & Drug Interactions in MDR-TB Patients. Indian Journal of Tuberculosis. Desember 2020;67(4):S69–78.
Soedarsono S, Mertaniasih NM, Kusmiati T, Permatasari A, Juliasih NN, Hadi C, dkk. Determinant Factors for Loss to Follow-up in Drug-Resistant Tuberculosis Patients: The Importance of Psycho-Social and Economic Aspects. BMC Pulmonary Medicine [Internet]. 2021 [dikutip 13 Juni 2023]; Tersedia pada: https://doi.org/10.1186/s12890-021-01735-9
Javaid A, Khan MA, Jan F, Rauf M, Khan MA, Basit A, dkk. Occurrence of Adverse Events in Patient Receiving Community-Based Therapy for Multidrug-Resistant Tuberculosis in Pakistan. Tuberk Toraks. Maret 2018;66(1):16–25.
Kementerian Kesehatan RI. Laporan Program Penanggulangan Tuberkulosis Tahun 2021. 2022.
Kementerian Kesehatan RI. Laporan Program Penanggulangan Tuberkulosis Tahun 2022. 2023.
Peraturan Presiden Republik Indonesia Nomor 67 tahun 2021 tentang Penanggulangan Tuberkulosis. Agustus, 2021.
Ganiyu AA, Avong YK, Akinyede A, Ige OM, El Tayeb O, Taleatu F, dkk. Prevalence of Adverse Drug Reactions to Second Line Anti Tuberculosis Drugs in Nigeria: A Cross-Sectional Study. JTR. 2021;09(02):90–102.
Grover G, Takkar J. Recent Advances in Multi-Drug-Resistant Tuberculosis and RNTCP. Indian J Community Med. 2008;33(4):219.
Ahmed A, Gudagunti AK, . S, Hagalur Nayak V, Swamy HM. Frequency and Type of Adverse Drug Reactions Related to Multidrug-Resistant Tuberculosis Therapy. Int J Adv Med. 2021;8(8):1086.
Gao JT, Du J, Wu GH, Pei Y, Gao MQ, Martinez L, dkk. Bedaquiline-Containing Regimens in Patients with Pulmonary Multidrug-Resistant Tuberculosis in China: Focus on the Safety. Infect Dis Poverty. Desember 2021;10(1):32.
Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, dkk. Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis. American Journal of Therapeutics. 2013;
Ahmad N, Javaid A, Syed Sulaiman SA, Afridi AK, Zainab, Khan AH. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients. American Journal of Therapeutics. 2018;25(5):e533–40.
Muñoz-Torrico M, Caminero-Luna J, Migliori GB, D’Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, dkk. Diabetes is Associated With Severe Adverse Events in Multidrug-Resistant Tuberculosis. Archivos de Bronconeumología (English Edition). 2017;53(5):245–50.
Nasasira M, Kalyango JN, Mupere E, Baluku JB. Incidence and Predictors of Adverse Drug Events Among People Receiving Drug Resistant Tuberculosis Treatment in Uganda: 8-Year Retrospective Cohort Study. Ther Clin Risk Manag. 2022;18:1117–27.
Merid MW, Gezie LD, Kassa GM, Muluneh AG, Akalu TY, Yenit MK. Incidence and Predictors of Major Adverse Drug Events Among Drug-Resistant Tuberculosis Patients on Second-Line Anti-Tuberculosis Treatment in Amhara Regional State Public Hospitals; Ethiopia: A Retrospective Cohort Study. BMC Infect Dis. 27 Maret 2019;19(1):286.
Atif M, Ahmed W, Nouman Iqbal M, Ahmad N, Ahmad W, Malik I, dkk. Frequency and Factors Associated With Adverse Events Among Multi-Drug Resistant Tuberculosis Patients in Pakistan: A Retrospective Study. Front Med. 1 Maret 2022;8:790718.
Ategyeka PM, Muhoozi M, Naturinda R, Kageni P, Namugenyi C, Kasolo A, dkk. Prevalence and Factors Associated with Reported Adverse-Events Among Patients on Multi-Drug-Resistant Tuberculosis Treatment in Two Referral Hospitals in Uganda. BMC Infect Dis. 10 Maret 2023;23(1):149.
Khan FU, Khan A, Khan FU, Hayat K, Rehman A ur., Chang J, dkk. Assessment of Adverse Drug Events, Their Risk Factors, and Management Among Patients Treated for Multidrug-Resistant TB: A Prospective Cohort Study From Pakistan. Frontiers in Pharmacology [Internet]. 2022 [dikutip 5 Oktober 2023];13. Tersedia pada: https://www.frontiersin.org/articles/10.3389/fphar.2022.876955
Yohanna KA, Isaakidis P, Hinderaker SG, Van den Bergh R, Ali E, Obembe BO, dkk. Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria. PLoS One. Maret 2015;10(3):e0120161.
Said A, Lyakurwa D, Sasi P, Mvungi H, Mpagama S, Mugusi S. Prevalence and Predictors of Adverse Events Among Patients Receiving Multi-Drug Resistant Tuberculosis Treatment at Kibong’oto Infectious Disease Hospital, Tanzania: A Retrospective Study. Tanzania Journal of Health Research. 26 Maret 2023;24(2):107–20.
Kushemererwa O, Nuwagira E, Kiptoo J, Yadesa TM. Adverse Drug Reactions and Associated Factors in Multidrug-Resistant Tuberculosis: A Retrospective Review of Patient Medical Records at Mbarara Regional Referral Hospital, Uganda. SAGE Open Medicine [Internet]. 2023 [dikutip 13 Juli 2023];11. Tersedia pada: http://journals.sagepub.com/doi/10.1177/20503121231171350
Rendon A, Tiberi S, Scardigli A, D’Ambrosio L, Centis R, Caminero JA, dkk. Classification of Drugs to Treat Multidrug-Resistant Tuberculosis ( MDR-TB): Evidence and Perspectives. J Thorac Dis. Oktober 2016;8(10):2666–71.
Winoto ES, Candradikusuma D. Shorter All-Oral Bedaquiline-Containing MDR-TB Regimen: The Backgrounds & Implementations. CRJIM. 3 Mei 2021;2(1):142–57.
Nilamsari WP, Rizqi MF, Regina NO, Wulaningrum PA, Fatmawati U. Adverse Drug Reaction and Its Management in Tuberculosis Patients with Multidrug Resistance: A Retrospective Study. Journal of Basic and Clinical Physiology and Pharmacology. 25 Juni 2021;32(4):783–7.
Swamy PN, Kumar VS. Prevalence of Adverse Drug Reactions Among MDR-TB Patients with Different Anti Tubercular Regimens. ijhs. 21 Agustus 2021;693–702.
Zhang Y, Wu S, Xia Y, Wang N, Zhou L, Wang J, dkk. Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An Ambispective Cohort Study. Med Sci Monit. 18 Mei 2017;23:2348–56.
Kurniawan AH, Cartika H, Aisyah S. Adverse Drug Reactions Associated with Successful Treatment of Multidrug-Resistant Tuberculosis Patients in Cempaka Putih Islamic Hospital Central Jakarta. Pharm Educ. 28 Juli 2021;21(2):15–21.
Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Velez-Segovia E, Soria-Montoya A, Nuñez-Garbin A, dkk. Factors Associated with Anti-Tuberculosis Medication Adverse Effects: A Case-Control Study in Lima, Peru. Pai M, editor. PLoS ONE. 16 November 2011;6(11):e27610.
Rifat M, Hall J, Oldmeadow C, Husain A, Hinderaker SG, Milton AH. Factors Related to Previous Tuberculosis Treatment of Patients with Multidrug-Resistant Tuberculosis in Bangladesh. BMJ Open. 8 September 2015;5(9):e008273.
Isaakidis P, Varghese B, Mansoor H, Cox HS, Ladomirska J, Saranchuk P, dkk. Adverse Events Among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India. PLoS One. 2012;7(7):e40781.
Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, dkk. Drug-Associated Adverse Events in the Treatment of Multidrug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis. Lancet Respir Med. 2020;8(4):383–94.
Chumovatov NV, Eremeev VE, Ergeshov AE. Effect of Tobacco Smoke and Nicotine on Immune Response in Tuberculosis Infection and Other Lung Diseases. Med immunol. 13 Juli 2022;24(3):455–62.
Ma Y, Che NY, Liu YH, Shu W, Du J, Xie SH, dkk. The Joint Impact of Smoking Plus Alcohol Drinking on Treatment of Pulmonary Tuberculosis. Eur J Clin Microbiol Infect Dis. 1 April 2019;38(4):651–7.
Massud A, Syed Sulaiman SA, Ahmad N, Shafqat M, Chiau Ming L, Khan AH. Frequency and Management of Adverse Drug Reactions Among Drug-Resistant Tuberculosis Patients: Analysis From a Prospective Study. Front Pharmacol. 2 Juni 2022;13:883483.
Asres A, Jerene D, Deressa W. Delays to Treatment Initiation Is Associated with Tuberculosis Treatment Outcomes Among Patients on Directly Observed Treatment Short Course in Southwest Ethiopia: A Follow-up Study. BMC Pulmonary Medicine. 2 Mei 2018;18(1):64.
Wagnew F, Gray D, Tsheten T, Kelly M, Clements ACA, Alene KA. Effectiveness of Nutritional Support to Improve Treatment Adherence in Patients with Tuberculosis: A Systematic Review. Nutrition Reviews [Internet]. 2023 [dikutip 19 November 2023];00(0):1-10. Tersedia pada: https://academic.oup.com/nutritionreviews/advance-article/doi/10.1093/nutrit/nuad120/7284364
Authors who publish with Journal of Public Health and Pharmacy retain the copyright of their work. The journal applies a Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA 4.0), which grants the following rights:
-
Copyright Retention: Authors retain the copyright of their work, maintaining full control over their intellectual property without restrictions.
-
Right of First Publication: Authors grant the journal the right of first publication of their work. This ensures that the work is initially published and credited in Journal of Public Health and Pharmacy.
-
License to Share and Reuse: The work is licensed under CC BY-SA 4.0, allowing others to copy, distribute, remix, and build upon the work for any purpose, even commercially, as long as proper credit is given to the authors, and any new creations are licensed under the same terms.
